De Luca Giacomo Ricercatore tempo determinato tipo aMedicineMED/50

Biography

Publications

Biography

Position & Professional Experience

  • Assistant Professor (Ricercatore Tempo Determinato di tipo A), Academic Discipline MED/50, Applied medical technology and methodology Position A at Vita-Salute San Raffaele University, Milan (Italy).
  • Consultant Rhematologist at Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) – IRCCS San Raffaele Hospital, Milan (Italy).
  • Head of Systemic Sclerosis & Cardiovascular Immunopathology Clinic at Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) – IRCCS San Raffaele Hospital, Milan (Italy).
  • Head of Myocarditis Clinic at Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) – IRCCS San Raffaele Hospital, Milan (Italy).

Education & Training

  • Medical School: Catholic University of the Sacred Heart Medical School, Rome, Italy, 2003-2009 (magna cum laude).
  • Resident in Rheumatology at Institute of Rheumatology and Affine Sciences of Catholic University in Rome (May 2010 - May 2015) (magna cum laude).

Clinical Experience

  • Consultant Rheumatologist at “Covid-19 Hub”, IRCCS San Raffaele Hospital (2020-2021).
  • Consultant Rheumatologist at Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) – IRCCS San Raffaele Hospital, Milan (Italy) (2015-2020)

Academic Experience

  • Assistant Professor (Ricercatore Tempo Determinato di tipo A), Academic Discipline MED/50, Applied medical technology and methodology Position A at Vita-Salute San Raffaele University, Milan (Italy) (September 2021 – ongoing).
  • Lecturer at Vita-Salute San Raffaele University (Milan, Italy), Academic Discipline MED/09 Internal Medicine – 06/B1 – Course Title “Clinical Rotations: Internal Medicine and Surgery I – APRO” School of Medicine and Surgery, International MD Program.
  • Lecturer at Vita-Salute San Raffaele University (Milan, Italy), Academic Discipline MED/09 Internal Medicine – 06/B1 – Course Title “Attività professionalizzante Semeiotica Generale” School of Medicine and Surgery.
  • Lecturer at Vita-Salute San Raffaele University (Milan, Italy), Course Title “Casi clinici complessi in immunologia clinica e reumatologia” (course coordinator) –  School of Medicine and Surgery.
  • Lecturer at Vita-Salute San Raffaele University (Milan, Italy) - Academic Discipline MED/16 - Course Title “Ulcere cutanee nei pazienti con malattie autoimmune: la Sclerodermia” –  School of Medicine and Surgery, I degree Master Wound Care.
  • Thesis co-Supervisor (n.9) – Experimental thesis in Clinical Immunology & Rheumatology at Vita-Salute San Raffaele School of Medicine (2017/2018 – 2018/2019 – 2019/2020 e 2020/2021).

Research Activity

  • Rheumatology Research Fellowship at Institute of Infection, Immunity and Inflammation - University of Glasgow – Glasgow (United Kingdom) - (June 2015 - November 2015).
  • “Assegno di Ricerca” at Vita-Salute San Raffaele University, Milan (Italy) – Project Title: “Primary cardiovascular involvement in Systemic Sclerosis” – Academic Discipline MED/16 – Rheumatology – Academic Recruitment Field: 06/D3 – Blood Diseases, Oncology and Rheumatology - June 2017 - May 2018.
  • “Assegno di Ricerca” at Vita-Salute San Raffaele University, Milan (Italy) – Project Title: “The role of periostin in Systemic Sclerosis” – Academic Discipline MED/16 – Rheumatology – Academic Recruitment Field: 06/D3 – Blood Diseases, Oncology and Rheumatology - June 2018 - May 2019.
  • “Assegno di Ricerca” at Vita-Salute San Raffaele University, Milan (Italy) – Project Title: “The role of periostin in Systemic Sclerosis” – Academic Discipline MED/16 – Rheumatology – Academic Recruitment Field: 06/D3 – Blood Diseases, Oncology and Rheumatology - June 2019 - April 2020.
  • Co-investigator for 12 funded grants & Clinical Trials.
  • Principal investigator (PI) of 3 funded grants finanziati & Clinical Trials.

Research Grant / Honor & Awards

  • Research Grant founded by the Italian Ministry of Health Ricerca Finalizzata 2019 – “DECIPHERING IL-1 MEDIATED INFLAMMATION FOR THE TARGETED TREATMENT OF DILATED CARDIOMYOPATHY”- Principal Investigator – 450k.
  • Research Grant founded by the Italian Ministry of Health Ricerca Finalizzata 2018 – “Myocarditis therapy with IL-1 inhibitor (MYTH-1): a randomized, double-blind, placebo-controlled, phase IIa monocentric study of subcutaneous anakinra plus standard of care versus standard of care for the treatment of virus-negative myocarditis” - Co-Principal Investigator – 450k.
  • Research Grant founded by Gruppo Italiano Lotta alla Sclerodermia (GILS Onlus) 2018 – “The impact of Mediterranean diet on depression, anxiety, gastrointestinal symptoms, nutritional status and overall quality of life in Systemic Sclerosis patients: an Italian epidemiologic survey” - Principal Investigator – 20k.
  • Outstanding Abstract - 1th Heart Involvement in Scleroderma Congress 2019 (Roma, Giugno 2019).
  • Outstanding Abstract - (G. De Luca, ABS 407), 4th Systemic Sclerosis World Congress 2016.
  • Oustanding Abstract – (EULAR annual meeting 2014, Paris, France).
  • Cora Notable Poster (Controversies in Rheumatology and Autoimmunity) congress 2013.
  • Fellow of Italian Society of Rheumatology (SIR)
  • Member of 3rd GISEA International Meeting - Biomarkers in Rheumatology Scientific Committee (Rome, Italy - 2013).
  • Member of 4th GISEA International Meeting - Biomarkers in Rheumatology Scientific Committee (Rome, Italy - 2014).
  • Scientific Coordinator of member of Scientific Committee of National Congress “Inibizione di IL-1 nel trattamento delle malattie infiammatorie” (IRCCS San Raffaele Hospital, Milan; 17-11-2017).
  • Member of “Working Group Myocardial and Pericardial diseases” of the European Society of Cardiology.
  • Member of Italian Study Group on “nailfold videocapillaroscopy and micro-circulation in rhematology” of the Italian Society of Rheumatology.
  • Member of Italian Study Group on “Interstitial Lung Disease in Rheumatic Diseases” of the Italian Society of Rheumatology.
  • Member of The European Scleroderma Trials and Research group (EUSTAR) & EUSTAR Young Investigator (YIG).

Scientific Production

84 original reports (published in international peer-review journals)

First author or co-author of more than 60 abstracts presented in international and national meetings.

ORCID ID: 0000-0002-5306-7714

Scopus Author ID: 7102935568

RESEARCH ID: AAB-2933-2019

h-index: 18 (fonte: Scopus)

(Nov. 2021)

Publications

 

ORCID ID: 0000-0002-5306-7714

Scopus Author ID: 7102935568

RESEARCH ID: AAB-2933-2019

h-index: 18 (fonte: Scopus)

List of publications:

 

  1. Caforio ALP, De Luca G, et al. Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in Systemic Sclerosis: frequency, clinical and prognostic correlates. Diagnostics 2021, 11, 2165. https://doi.org/10.3390/diagnostics11112165. Journal of Rheumatology November 2021,  jrheum.210794; DOI: https://doi.org/10.3899/jrheum.210794.
  2. De Angelis R, Giuggioli D, Bajocchi G, et al. Gender-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study from the National Registry of the Italian Society Of Rheumatology.
  3. Bruni C, Buch MH, Furst DE, De Luca G, et al. Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders. October 2021. doi:10.1177/23971983211053246.
  4. Campochiaro C, De Luca G, Dagna L. Cardiac immune-related adverse events: an immune-cardio-oncology puzzle. Eur J Heart Fail. 2021 Aug 12. doi: 10.1002/ejhf.2329. 
  5. Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Dagna L, Tavoni A, Caso F, Ursini F, Piero R, Caminiti M, Foti R, Riccieri V, Guiducci S, Pellegrini R, Zanatta E, Varcasia G, Olivo D, Gigliotti P, Cuomo G, Murdaca G, Cecchetti R, De Angelis R, Romeo N, Ingegnoli F, Cozzi F, Codullo V, Cavazzana I, Colaci M, Abignano G, De Santis M, Lubrano E, Fusaro E, Rossa AD, Spinella A, Lumetti F, De Luca G, et al. Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. Curr Pharm Des. 2021 Sep 2. doi: 10.2174/1381612827666210903103935. 
  6. Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, Alessandra B, Signorelli D, Palmisano A, Vignale D, Peretto G, Sala S, Esposito A, Garassino M, Gregorc V, Dagna L. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med. 2021 Aug 11:S0953-6205(21)00266-1. doi: 10.1016/j.ejim.2021.07.016.
  7. Agostini E, De Luca G, Bruni C, et al. Intravenous Immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. Autoimmun Rev. 2021 Oct 28:102981. doi: 10.1016/j.autrev.2021.102981. 
  8. Campochiaro C, De Luca G, Farina N, Vignale D, Palmisano A, Matucci-Cerinic M, Dagna L. Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosis. Scand J Rheumatol. 2021 Jul 7:1-3. doi: 10.1080/03009742.2021.1932582.
  9. Lescure FX, Honda H, Fowler RA, et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. Lancet Respiratory Medicine 2021. DOI:https://doi.org/10.1016/S2213-2600(21)00099-0.
  10. Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C, Bellando-Randone S, Blagojevic J, Melchiorre D, Hughes M, Denton CP, Luppi F, Ruaro B, Della Casa F, Rossi FW, De Luca G, et al. THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. Rheumatology (Oxford). 2021 Jul 28:keab615. doi: 10.1093/rheumatology/keab615.
  11. De Luca G, Tomelleri A, Dagna L, Matucci-Cerinic M. The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. Clin Rheumatol. 2021 Jul;40(7):2529-2533. doi: 10.1007/s10067-021-05733-4.
  12. Biavasco R, Molteni R, Stefanoni D, Nemkov T, Netea MG, Domínguez-Andrés J, Arts RJ, Merelli I, Mazza D, Zambrano S, Panigada M, Cantoni E, Tengesdal I, Maksud P, Piras F, De Luca G, et al. Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. Blood. 2021 Jun 2:blood.2020009594. doi: 10.1182/blood.2020009594.
  13. Peretto G, Villatore A, Rizzo S, Esposito A, De Luca G, et al.  The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. J. Clin. Med. 2021, 10, 1974. https://doi.org/10.3390/jcm10091974.
  14. Della-Torre E, Lanzillotta M, Campochiaro C, Cavalli G, De Luca G, et al. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front. Immunol 2021. https://doi.org/10.3389/fimmu.2021.675678.
  15. De Luca G, Cavalli G, Campochiaro C, et al. Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. Front. Immunol., 23 March 2021. https://doi.org/10.3389/fimmu.2021.653950.
  16. Tomelleri A, Campochiaro C, De Luca G, et al. Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease. Expert Opinion on Orphan Drugs 2021. https://doi.org/10.1080/21678707.2021.1904395.
  17. Cavalli G, De Luca G, Doglioni C, Ferrero E, Ferrarini M, Dagna L. A Novel Histiocytosis With Synovial and Skin Involvement. Ann Intern Med. 2021 Feb;174(2):273-274. doi: 10.7326/L20-0092.
  18. Lazzaroni MG, Marasco E, Campochiaro C, DeVries-Bouwstra J, Gonzalez-Perez MI, Rojas-Serrano J, Hachulla E, Zanatta E, Barsotti S, Furini F, Triantafyllias K, Abignano G, Truchetet ME, De Luca G, et al. The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology (Oxford, England). 2021 Feb. DOI: 10.1093/rheumatology/keab152.
  19. Ferri C, Giuggioli D, Raimondo V, Dagna L, Riccieri V, Zanatta E, Guiducci S, Tavoni A, Foti R, Cuomo G, De Angelis R, Cozzi F, Murdaca G, Cavazzana I, Romeo N, Codullo V, Ingegnoli F, Pellegrini R, Varcasia G, Rossa AD, De Santis M, Abignano G, Colaci M, Caminiti M, L'Andolina M, Lubrano E, Spinella A, Lumetti F, De Luca G, et al; COVID-19 & Autoimmune Systemic Diseases Italian Study Group. COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. Lancet Rheumatol. 2021 Jan 12. doi: 10.1016/S2665-9913(21)00007-2. PMID: 33521657; PMCID: PMC7836813.
  20. Lazzaroni MG, Campochiaro C, Bertoldo E, De Luca G, Caimmi C, Tincani A, Franceschini F, Airò P. Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis. Clin Exp Rheumatol. 2020 Dec 2. PMID: 33337991.
  21. Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca G, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatology 2021. DOI:https://doi.org/10.1016/S2665-9913(21)00012-6.
  22. Campochiaro C, Farina N, Tomelleri A, De Luca G, Baldissera E, Cavalli G, Dagna L. Drug retention rates of biological agents in adult onset Still's disease. Semin Arthritis Rheum. 2020 Dec 11;51(1):1-6. doi: 10.1016/j.semarthrit.2020.09.014. PMID: 33340821.
  23. Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E, Tomelleri A, Dagna L. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol. 2020 Dec 18;11:598308. doi: 10.3389/fphar.2020.598308. PMID: 33442386; PMCID: PMC7798432.
  24. Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, Muccini C, Monti G, De Luca G, et al; COVID-BioB study group. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2020 Oct 24:S1198-743X(20)30652-2. doi: 10.1016/j.cmi.2020.10.021. PMID: 33223114; PMCID: PMC7584496.
  25. Cavalli G, Cariddi A, Ferrari J, Suzzi B, Tomelleri A, Campochiaro C, De Luca G, Baldissera E, Dagna L. Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. Rheumatology (Oxford). 2021 Jan 5;60(1):465-467. doi: 10.1093/rheumatology/keaa738. PMID: 33188686; PMCID: PMC7717382.
  26. Natalello G, De Luca G, Gigante L, et al. Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvascular Research 133 (2021) 1040712. https://doi.org/10.1016/j.mvr.2020.104071.
  27. De Luca G, Cavalli G, Campochiaro C, et al. Mavrilimumab for severe COVID-19: author’s reply. Lancet Rheumatology 2020. doi:https://doi.org/10.1016/S2665-9913(20)30308-8.
  28. Peretto G, Sala S, Basso C, Rizzo S, Radinovic A, Frontera A, De Luca G, et al. Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis. JACC 2020. https://doi.org/10.1016/j.jacc.2020.08.012.
  29. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Ciceri F, Zangrillo A, Dagna L. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli. Ann Rheum Dis. 2020 Jul 31:annrheumdis-2020-218612. doi: 10.1136/annrheumdis-2020-218612. PMID: 32737105.
  30. Peretto G, De Luca G, Campochiaro C, et al. Telemedicine in myocarditis: Evolution of a mutidisciplinary “disease Unit” at the time of COVID-19 pandemic. Am Heart J. 2020;doi:10.1016/j.ahj.2020.07.015.
  31. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 2020;79:1277–1285. doi:10.1136/annrheumdis-2020-218122.
  32. Bruni C, De Luca G, Lazzaroni MG, et al. Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. Eur J Intern Med. 2020;S0953-6205(20)30235-1. doi:10.1016/j.ejim.2020.05.042.
  33. De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e465-e473. doi: 10.1016/S2665-9913(20)30170-3. 
  34. Sala S, Peretto G, De Luca G, et al. Low prevalence of arrhythmias in clinically stable COVID-19 patients. Pacing and clinical electrophysiology. PACE, 10.1111/pace.13987. Advance online publication. https://doi.org/10.1111/pace.13987.
  35. Peretto G, Sala S,  De Luca G, et al. Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias. J Am Coll Cardiol EP. 2020 Jun 24. DOI:10.1016/j.jacep.2020.05.013.
  36. Campochiaro C, De Luca G, Lazzaroni MG, et al. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study, Rheumatology, keaa136, https://doi.org/10.1093/rheumatology/keaa136.
  37. De Luca G, Campochiaro C, Sartorelli S, Peretto G, Dagna L. Therapeutic strategies for virus-negative myocarditis: a comprehensive review. Eur J Intern Med. 2020;77:9-17. doi:10.1016/j.ejim.2020.04.050.
  38. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43-49. doi:10.1016/j.ejim.2020.05.021.
  39. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325-e331. doi:10.1016/S2665-9913(20)30127-2.
  40. Ferri C, Giuggioli D, Guiducci S, Lumetti F, Bajocchi G, Magnani L, Codullo V, Ariani A, Girelli F, Riccieri V, Pellegrino G, Bosello S, Foti R, Visalli E, Amato G, Benenati A, Cuomo G, Iannone F, Cacciapaglia F, De Angelis R, Ingegnoli  F, Talotta R, Campochiaro C, Dagna L, De Luca G, et al. Italian Society of Rheumatology (SIR). Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum. Clin Exp Rheumatol. 2020 May-Jun;38 Suppl 125(3):40-47. PMID: 32301427.
  41. Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, De Luca G, Sala S, Ferro P, Basso C, Del Maschio A, De Cobelli F, Esposito A. Hybrid FDG-PET/MR or FDG-PET/CT to Detect Disease Activity in Patients With Persisting Arrhythmias After Myocarditis. JACC Cardiovasc Imaging. 2020 Apr 10. pii: S1936-878X(20)30266-7. doi: 10.1016/j.jcmg.2020.03.009.
  42. Peretto G, Sala S, Rizzo S, Palmisano A, Esposito A, De Cobelli F, Campochiaro C, De Luca G, Foppoli L, Dagna L, Thiene G, Basso C, Della Bella P. Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation. J Am Coll Cardiol. 2020 Mar 10;75(9):1046-1057. doi: 10.1016/j.jacc.2020.01.036.
  43. Pauling JD, Caetano J, Campochiaro C, De Luca G, Gheorghiu AM, Lazzaroni MG, Khanna D. (2019). Patient-reported outcome instruments in clinical trials of systemic sclerosis. Journal of Scleroderma and Related Disordershttps://doi.org/10.1177/2397198319886496.
  44. Campochiaro C, Tomelleri A, Sartorelli S, Cavalli G, De Luca G, Baldissera E, Dagna L. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Semin Arthritis Rheum. 2020 Jan 25. pii: S0049-0172(20)30005-6. doi: 10.1016/j.semarthrit.2020.01.005.
  45. De Luca G, Campochiaro C, De Santis M, Sartorelli S, Peretto G, Sala S, Canestrari G, De Lorenzis E, Basso C, Rizzo S, Thiene G, Palmisano A, Esposito A, Selmi C, Gremese E, Della Bella P, Dagna L, Bosello SL. Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatology (Oxford). 2020 Sep 1;59(9):2523-2533. doi: 10.1093/rheumatology/kez658. PMID: 31990340.
  46. Campochiaro C, De Luca G, De Santis M. Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis. Ann Rheum Dis. 2019 Aug 3. pii: annrheumdis-2019-216070. doi: 10.1136/annrheumdis-2019-216070.
  47. Tomelleri A, Campochiaro C, Sartorelli S, Papa M, De Luca G, Cavalli G, Baldissera E, Dagna L. Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. J Rheumatol. 2019 Dec 15. pii: jrheum.190862. doi: 10.3899/jrheum.190862.
  48. Campochiaro C, Cavalli G, Farina N, Tomelleri A, De Luca G, Dagna L. Efficacy  and improved tolerability of combination therapy with interleukin-1 blockade and  MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. Ann Rheum Dis. 2019 Dec 9. pii: annrheumdis-2019-216610. doi: 10.1136/annrheumdis-2019-216610.
  49. Campochiaro C, De Luca G, Tomelleri A, Sartorelli S, Peretto G, Sala S, Palmisano A, Esposito A, Cavalli G, Dagna L. Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use. J Clin Rheumatol. 2019 Nov 19. doi: 10.1097/RHU.0000000000001194.
  50. Imazio M, Andreis A, De Ferrari GM, Cremer PC, Mardigyan V, Maestroni S, Luis  SA, Lopalco G, Emmi G, Lotan D, Marcolongo R, Lazaros G, De Biasio M, Cantarini L, Dagna L, Cercek AC, Pivetta E, Varma B, Berkson L, Tombetti E, Iannone F, Prisco D, Caforio ALP, Vassilopoulos D, Tousoulis D, De Luca G, Giustetto C, Rinaldi M, Oh JK, Klein AL, Brucato A, Adler Y. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol.  2019 Oct 15:2047487319879534. doi: 10.1177/2047487319879534.
  51. De Luca G, Campochiaro C, Sartorelli S, et al. Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study. J Autoimmun. 2019 Sep2:102330. doi: 10.1016/j.jaut.2019.102330.
  52. Zizzo G, De Santis M, Bosello S, Tolusso B, Alivernini S, De Luca G, Gremese E, Ferraccioli G. Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers. Eur J Immunol. 2019 Aug 10. doi: 10.1002/eji.201847849.
  53. De Luca G, Cariddi A, Campochiaro C, Vanni D, Boffini N, Tomelleri A, Cavalli G, Dagna L. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020 Jan 1;59(1):171-175. doi: 10.1093/rheumatology/kez267. 
  54. Tomelleri A, Campochiaro C, Sartorelli S, Cavalli G, De Luca G, et al. Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. Scand J Rheumatol. 2019 May 8:1-9. doi: 10.1080/03009742.2019.1581838.
  55. De Luca G, Campochiaro C, Dagna L. Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. J Rheumatol. 2019 Jul 1. pii: jrheum.190078. doi:10.3899/jrheum.190078.
  56. Peretto G, Sala S, Rizzo S, De Luca G, Campochiaro C, Sartorelli S, Bendetti G, Palmisano A, Esposito A, Tresoldi M, Thiene G, Basso C, Della Bella P. Arrhythmias in myocarditis: state of the art. Heart Rhythm. 2018 Nov 24. pii: S1547-5271(18)31169-X. doi: 10.1016/j.hrthm.2018.11.024.
  57. Sartorelli S, Campochiaro C, De Luca G. Diagnostic approach and novel therapeutic option for cardiac inflammatory disorders. Comment of "Antisynthetase syndrome and cardiac involvement: a rare association" by Meudec et al. Joint Bone Spine 2018. doi: 10.1016/j.jbspin.2018.09.019. Joint Bone Spine. 2019 Feb 7. pii: S1297-319X(19)30018-1. doi:10.1016/j.jbspin.2019.01.021.
  58. Sartorelli S, De Luca G, Campochiaro C, Peretto G, Sala S, Esposito A, Busnardo E, Basso C, Thiene G, Dagna L. Successful use of sirolimus in a patient  with cardiac microangiopathy in primary antiphospholipid syndrome. Scand J Rheumatol. 2019 Feb 22:1-2. doi: 10.1080/03009742.2019.1574022.
  59. Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello CA, Baldissera E,  Dagna L. Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019 Feb 13;21(1):54. doi: 10.1186/s13075-019-1843-9.
  60. Peretto G, Sala S, De Luca G, et al. Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. Int J Cardiol. 2019 Apr 1;280:110-116. doi: 10.1016/j.ijcard.2018.11.104.
  61. Bosello S, De Luca G, Berardi G, Canestrari G, de Waure C, Gabrielli FA, et al. Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. Eur J Intern Med. 2018 Oct 23. pii: S0953-6205(18)30406-0. doi: 10.1016/j.ejim.2018.10.013.
  62. Cavalli G, De Luca G, Dagna L. Large-Vessel Vasculitides: Takayasu Arteritis and Giant Cell Arteritis. Visceral Vessels and Aortic Repair, chapter 35. doi: 10.1007/978-3-319-94761-7_35. 

  63. De Luca G, Campochiaro C, Sartorelli S, Franchini S, Candela C, Peretto G, Sala S, Dagna L. Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous Systemic Sclerosis: a case report. Scand J Rheum 2018. Scand J Rheumatol. 2018 Sep 30:1-2. doi: 10.1080/03009742.2018. 

  64. Campochiaro C, De Luca G, Sartorelli S, Tomelleri A, Esposito A, Candela C, Cavalli C, Dagna L. Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: a Case Series. J Clin Rheum 2018. J Clin Rheumatol. 2018 Sep 18. doi: 10.1097/RHU.0000000000000897. 

  65. Tomelleri A, Campochiaro C, De Luca G, Cavalli G, Dagna L. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med. 2018 Jul 31. pii: S0953- 6205(18)30295-4. doi: 10.1016/j.ejim.2018.07.023.
  66. De Luca G, Campochiaro C, Dinarello CA, Dagna L, Cavalli G. Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. Ann Intern Med. 2018 Jul 31. doi: 10.7326/L18- 0315.
  67. Tomelleri A, Cavalli G, De Luca G, Campochiaro C, D’Aliberti T, Tresoldi M, Dagna L. Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease. Front. Immunol. 9:1233. doi: 10.3389/fimmu.2018.01233. 

  68. De Luca G, Cavalli G, Campochiaro C, Tresoldi M, Dagna L. Myocarditis: An Interleukin-1- Mediated Disease?. Front. Immunol. 9:1335. doi: 10.3389/fimmu.2018.01335. 

  69. De Luca G, Campochiaro C, Cavalli G, Dagna L. Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? Eur Rev Med Pharmacol Sci. 2018 Apr;22(8):2189-2190. doi: 10.26355/eurrev_201804_14801. 

  70. De Luca G, Campochiaro C, Cavalli G, Dagna L. Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance. J Clin Rheumatol. 2018 Apr 16. doi: 10.1097/RHU.0000000000000792.
  71. Pacini G, Cavalli G, Tomelleri A, De Luca G, et al. The Fibrogenic Chemokine CCL18 is Associated with Disease Severity in Erdheim-Chester Disease. OncoImmunology 2018. DOI: 10.1080/2162402X.2018.1440929. 

  72. Campochiaro C, De Luca G, Cavalli G. Letter by Campochiaro et al Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related 
Cardiotoxicity". Circulation. 2018 May 29;137(22):2421-2422. doi: 10.1161/CIRCULA TIONAHA.117.033305.
  73. Chiapparini L, Cavalli G, Langella T, Venerando A, De Luca G, Raspante S, et al. Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim- Chester disease. J Neurol. 2018 Feb;265(2):273-284. doi: 10.1007/s00415-017-8692-8. PMID: 29204962.
  74. Ramirez GA, De Luca G, Dell' Antonio G, Baldissera E, Suma GV, Tresoldi M, Dagna L. C3-glomerulopathy and MGUS: the skin beyond the kidney. QJM. 2018 Mar 1;111(3):187-188. doi: 10.1093/qjmed/hcx254. PMID: 29272460.
  75. De Luca G, Bosello SL, Canestrari G, Cavalli G, Dagna L, Ferraccioli G. QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. Int J Cardiol. 2017 Jul 15;239:33. doi: 10.1016/j.ijcard.2017.03.088. PMID: 28560978.
  76. De Luca G, Cavalli G, Baldissera E, Dagna L. Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al. Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):221. PMID: 28375830.
  77. Cavalli G, De Luca G, Dagna L. Advances in Potential Targeted Therapies for Erdheim-Chester Disease. Cavalli, G. et al. “Advances in potential targeted therapies for Erdheim-Chester disease.” Expert Opinion on Orphan Drugs 5 (2017): 253 - 260. DOI:10.1080/21678707.2017.1285226.
  78. De Luca G, Bosello S, Leone AM, Gabrielli F, Pelargonio G, Inzani F, Crea F, Ferraccioli G. Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst. Scand J Rheumatol. 2017 Jan;46(1):78-80. doi: 10.3109/03009742.2016.1157626. PMID: 27098649.
  79. De Luca G, Bosello S, Gabrielli FA, et al. Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. PLoS One. 2016 Apr 21;11(4):e0153012. doi: 10.1371/journal.pone.0153012.
  80. Bosello S, De Luca G, Ferraccioli G. Troponin in Stable Ischemic Heart Disease and Diabetes. N Engl J Med. 2015 Nov 12;373(20):1977-8. DOI: 10.1056/NEJMc1511645. 

  81. De Luca G, Bosello S, Berardi G, et al. Tumor associated antigens in Systemic Sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. Rheumatology (Oxford). 2015 Jun 22. pii: kev204. doi: 10.1093/rheumatology/kev204. Epub 2015 Jun 22. PMID: 26106211.
  82. Bosello S, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, Pirronti T, Ferraccioli G. Long- term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2014 Sep 8. pii: S0049-0172(14)00218-2. 

  83. Pieroni M, De Santis M, Zizzo G, Bosello S, Smaldone C, Campioni M, De Luca G, Laria A, Meduri A, Bellocci F, Bonomo L, Crea F, Ferraccioli G.Recognizing and treating myocarditis in recent- onset systemic sclerosis heart disease: Potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 2014 Feb;43(4):526-35. doi: 10.1016/j.semarthrit.2013.07.006.
  84. Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G. B cells in Systemic Sclerosis: a possible target for therapy. Autoimmuninty reviews 2011 aug;10(10):624-30.

 

Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.